| Patents for A61P 9 - Drugs for disorders of the cardiovascular system (159,484) |
|---|
| 04/08/2009 | CN101401789A Cordyceps sinensis polysaccharide liposome medicament and preparation thereof |
| 04/08/2009 | CN100475939C A process for decreasing environmental pollutants in an oil or a fat, a volatile environmental pollutants decreasing working fluid, a health supplement and an animal feed product |
| 04/08/2009 | CN100475843C Peptides effective in the treatment of tumors and other conditions requiring the removal or destruction of cells |
| 04/08/2009 | CN100475829C Sugar-substituted 2-azetidinones useful as hypocholesterolemic agents |
| 04/08/2009 | CN100475816C Reverse-turn mimetics and method relating thereto |
| 04/08/2009 | CN100475810C Novel 2-arylthiazole compounds as pparalpha and ppargamma agonists |
| 04/08/2009 | CN100475804C Isochromanone 4 derivate, preparation process and therapeutic use thereof |
| 04/08/2009 | CN100475793C Quinazoline derivatives and use for preparing medicine |
| 04/08/2009 | CN100475757C Substance for use in dietary supplementation or for prepn. of medicament for treating non-insulin dependent diabetes mellitus, Hypertension and/or metabolic syndrome |
| 04/08/2009 | CN100475267C Liquid formulations with a high concentration of human growth hormone (hgh) comprising glycin |
| 04/08/2009 | CN100475261C A Chinese medicine for treating cardiovascular and cerebrovascular disease |
| 04/08/2009 | CN100475259C Medicine for treating cerebral infarction |
| 04/08/2009 | CN100475239C Quality control method of heart pulse free flow oral preparation |
| 04/08/2009 | CN100475234C Injetio for treating coronary heart disease and preparation process thereof |
| 04/08/2009 | CN100475233C Combination of Chinese traditional medicine for treating angina pectoris as well as preparation method and usage |
| 04/08/2009 | CN100475229C Composition for preventing atherosclerosis |
| 04/08/2009 | CN100475224C Chinese medicine extract and application thereof |
| 04/08/2009 | CN100475222C Beewax essence millimicrosphere preparation and uses in medicine |
| 04/08/2009 | CN100475220C Medicine for treating cardiocerebral vascular disease and preparing method thereof |
| 04/08/2009 | CN100475219C Use of liposoluble stilbene glycoside kind compound in treating ischemic heart brain blood vessel disease and preparation thereof |
| 04/08/2009 | CN100475061C Combinations of vasoprotective agents and formulations containing the agents |
| 04/07/2009 | US7514571 Bicyclo derivative |
| 04/07/2009 | US7514564 Substituted amine derivatives and methods of use |
| 04/07/2009 | US7514471 2S)-3-(4-{2-[(Cyclohexylmethyl)(heptyl)amino]-2-oxoethoxy}phenyl)-2-ethoxypropanoic acid; treating lipid disorders (dyslipidemias), insulin resistance |
| 04/07/2009 | US7514469 Cyclooxygenase inhibitors; osteoarthritis, rheumatoid arthritis, and other injuries that result from overuse |
| 04/07/2009 | US7514467 Novel polymorphic form IV and solvate; precipitation from ethyl acetate |
| 04/07/2009 | US7514456 Nicotinamide derivatives useful as p38 inhibitors |
| 04/07/2009 | US7514452 3-(4-hexylphenyl)-2-furancarboxylic acid 2-(4-hydroxy-3-nitrobenzoyl)hydrazide; nonpeptidergic glucagon receptor antagonist; orally; decrease blood sugar levels; hypoglycemic agent; dabetes mellitus type I and II, obesity, hyperlipidemia, gastrointestinal disorders |
| 04/07/2009 | US7514449 inhibitor of activated blood coagulation factor X; N-(5-chloropyridin-2-yl)-3- {[(trans-4-pyrrolidin-1 -ylcyclohexyl)carbonyl]aznino}furo[3,2-c]pyridine-2-carboxaxnide; disorders caused by thrombi and emboli in a mammal; decreased toxicity, and causes few side effects |
| 04/07/2009 | US7514429 Benzoxazinone-derived compounds, their preparation and use as medicaments |
| 04/07/2009 | US7514422 To treat obesity, schizophrenia, anxiety, depression, alcoholism; using 3-benoazepine compounds like 8-chloro-1-methyl-2,3,4,5-tetrahydro-1H-3-benzazepine (lorcaserin); serotonin 2c receptor agonists |
| 04/07/2009 | US7514398 Growth factor complex |
| 04/07/2009 | US7514239 Nucleotide sequences coding polypeptide for use in the treatment of preferential glandular disorders |
| 04/07/2009 | US7514225 detecting drugs that inhibits the binding of macrophage migration inhibitory factor (MIF) to an antimacrophage migration inhibitor factor monoclonal or polyclonal antibody; drug screening |
| 04/07/2009 | US7514107 Treatment of diseases involving defective gap junctional communication |
| 04/07/2009 | US7514105 Bioavailability/bioefficacy enhancing activity of Cuminum cyminum and extracts and fractions thereof |
| 04/07/2009 | US7514103 Combat/reversion of spontaneous and electrical stimulus-induced ventricular fibrillation; cardiovascular disorders |
| 04/07/2009 | US7514098 Use of targeted cross-linked nanoparticles for in vivo gene delivery |
| 04/07/2009 | US7514084 isolated nonapeptide that bind to an human leukocyte antigen (HLA-A 0201) restricted T cell receptors with high affinity and induce a high cytotoxic T lymphocyte response, used for treating or preventing tumors and cancers |
| 04/07/2009 | US7514072 Method for the treatment of cerebral ischaemia and use of erythropoietin or erythropoietin derivatives for the treatment of cerebral ischaemia |
| 04/07/2009 | CA2493633C Kinase inhibitors |
| 04/07/2009 | CA2490152C Oxazole derivatives and their use as insulin sensitizers |
| 04/07/2009 | CA2463294C Inhibitors of human phosphatidyl-inositol 3-kinase delta |
| 04/07/2009 | CA2458684C Pyrrolo pyrimidines as agents for the inhibition of cystein proteases |
| 04/07/2009 | CA2436438C 4-aminobenzopyran derivatives |
| 04/07/2009 | CA2415890C N-oxides as nk1 receptor antagonist prodrugs of 4-phenyl-pyridine derivatives |
| 04/07/2009 | CA2400554C Pyrimidine-4-one derivatives as ldl-pla2 inhibitors |
| 04/07/2009 | CA2390116C Triphenylalkene derivatives and their use as selective estrogen receptor modulators |
| 04/07/2009 | CA2383583C Benzopyran derivative |
| 04/07/2009 | CA2373880C Isoquinoline derivatives or salts thereof |
| 04/07/2009 | CA2372384C Anti-inflammatory bioactive glass particulates |
| 04/07/2009 | CA2361998C Aromatic heterocyclic compounds as anti-inflammatory agents |
| 04/07/2009 | CA2341991C Pyrroloindoles, pyridoindoles and azepinoindoles as 5-ht2c agonists |
| 04/07/2009 | CA2339253C Inhibitors of p38 |
| 04/07/2009 | CA2330487C Administration of resveratrol to prevent or treat restenosis following coronary intervention |
| 04/07/2009 | CA2311643C Compositions and methods for inducing gene expression |
| 04/07/2009 | CA2297097C Compositions, kits, and methods for inhibiting cerebral neurovascular disorders and muscular headaches |
| 04/07/2009 | CA2256633C Selected derivatives of k-252a |
| 04/02/2009 | WO2009043031A2 Microbubbles and methods for oxygen delivery |
| 04/02/2009 | WO2009042970A1 N-hydroxylsulfonamide derivatives as new physiologically useful nitroxyl donors |
| 04/02/2009 | WO2009042922A2 Peptide-peptidase inhibitor conjugates and methods of making and using same |
| 04/02/2009 | WO2009042544A1 Quinone derivatives, pharmaceutical compositions, and uses thereof |
| 04/02/2009 | WO2009042213A1 Methods of treating or preventing cardiac disease associated with a high fat diet |
| 04/02/2009 | WO2009041714A1 External preparation for free radical diseases |
| 04/02/2009 | WO2009041559A1 Indazole acrylic acid amide compound |
| 04/02/2009 | WO2009041521A1 Quinolone derivative |
| 04/02/2009 | WO2009041037A1 Drug for suppressing pathogen occurring in vivo |
| 04/02/2009 | WO2009040288A1 1,1,1-trifluoro-2-hydroxy-3-phenylpropane derivatives |
| 04/02/2009 | WO2009040089A2 Use of the peptides maippkknqdk (cow kappa casein 106-116) and/or ygfqna (serorphin) as therapeutic agents |
| 04/02/2009 | WO2009040088A1 Use of peptide kvlpvpq as a therapeutic agent |
| 04/02/2009 | WO2009040087A2 Therapeutic use of peptide yglf and combination with kvlpvpq |
| 04/02/2009 | WO2009040086A2 Use of salusin-alpha as a therapeutic agent |
| 04/02/2009 | WO2009040085A2 Use of exendin-4 and optionally salusin-alpha as therapeutic agent(s) |
| 04/02/2009 | WO2009040084A2 Use of a peptide as a therapeutic agent |
| 04/02/2009 | WO2009040083A2 Use of a peptide as a therapeutic agent |
| 04/02/2009 | WO2009040073A2 Use of a peptide as a therapeutic agent |
| 04/02/2009 | WO2009040072A2 Use of angiotensin i as a therapeutic agent in the treatment of eg aids or tuberculosis |
| 04/02/2009 | WO2009040071A2 Use of cyclo-rgdfv and optionally angiotensin i as therapeutic agents in the treatment of eg aids or tuberculosis |
| 04/02/2009 | WO2009040070A2 Use of helodermin as a therapeutic agent |
| 04/02/2009 | WO2009040069A2 Use of bq-610 alone or in combination with helodermin as a therapeutic agent |
| 04/02/2009 | WO2009040068A2 Use of a peptide as a therapeutic agent |
| 04/02/2009 | WO2009040067A2 Use of a peptide as a therapeutic agent |
| 04/02/2009 | WO2009040051A2 Use of the peptide rfmwmk alone or in combination with the peptide ymdgtmsqv as a therapeutic agent |
| 04/02/2009 | WO2009040050A2 Use of calcitonin as anti-angiogenic agent |
| 04/02/2009 | WO2009040049A2 Use of acetyl- (ala10, 11)-rantes (1-14) and/or calcitonin as anti-angiogenic agents |
| 04/02/2009 | WO2009040048A2 Use of the c-reactive peptide as a therapeutic agent |
| 04/02/2009 | WO2009040047A2 Therapeutic uses of ghrelin and combinations with stresscopin |
| 04/02/2009 | WO2009040046A2 Use of stresscopin-related peptide as a therapeutic agent |
| 04/02/2009 | WO2009040045A2 Use of tyr-w-mif-1 and urocortin 2 as therapeutic agents |
| 04/02/2009 | WO2009040036A2 Use of a galanin peptide as a therapeutic agent |
| 04/02/2009 | WO2009040035A2 Use of a peptide as a therapeutic agent |
| 04/02/2009 | WO2009040034A2 Use of a peptide as a therapeutic agent |
| 04/02/2009 | WO2009040033A2 Use of a peptide as a therapeutic agent |
| 04/02/2009 | WO2009040032A2 Use of a peptide as a therapeutic agent |
| 04/02/2009 | WO2009040031A2 Use of a peptide as a therapeutic agent |
| 04/02/2009 | WO2009040030A1 Use of a peptide as a therapeutic agent |
| 04/02/2009 | WO2009040029A2 Use of adrenomedullin as a therapeutic agent for the treatment of excessive angiogenesis |
| 04/02/2009 | WO2009040028A2 Use of casoxin c and optionally adrenomedullin as therapeutic agents for the treatment of excessive angiogenesis |
| 04/02/2009 | WO2009040027A1 Use of the peptide stresscopin as a therapeutic agent |
| 04/02/2009 | WO2009040025A2 Use of neuropeptide sf, alone or in combination with glp-2, as a therapeutic agent |